Duration of antiplatelet drugs for drug-eluting stents studied

Duration of antiplatelet drugs for drug-eluting stents studied
In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology.

(HealthDay)—In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology.

In the first study, Ignacio Ferreira-González, M.D., Ph.D., from Vall d'Hebron Hospital in Barcelona, Spain, and colleagues conducted a study involving 1,622 patients undergoing drug-eluting stent implantation. The patients were assessed at regular intervals up to a year post-implantation. During that time, 10.6 percent interrupted at least one antiplatelet drug; 64.5 percent of the interruptions were temporary. The researchers found that the rate of major cardiac events was similar in patients who continued or interrupted treatment.

In the second study, Byeong-Keuk Kim, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues randomly assigned 2,117 patients with coronary artery stenosis to receive a zotarolimus-eluting stent with three months of dual or another drug-eluting stent with twelve months of dual antiplatelet therapy. The researchers found that both groups had similar rates of a primary composite end point of , , stent thrombosis, target or vessel revascularization, or bleeding at one year (4.7 percent in each group).

"With newer-generation drug-eluting stents, six months [of] dual antiplatelet therapy might be sufficient, and three months not completely off-the-wall in low-risk groups," Bernhard Witzenbichler, M.D., from Charité-Campus Benjamin Franklin in Berlin, writes in an accompanying editorial. "However, the patient- and device-related criteria safely allowing early dual antiplatelet therapy withdrawal or interruption still have to be determined."

The Ferreira-González study was partially funded by Bristol-Myers Squibb; two authors disclosed financial ties to drug and device companies. Two authors from the Kim study disclosed to Medtronic.

More information: Abstract - Ferreira-González
Full Text
Abstract - Kim
Full Text
Editorial

add to favorites email to friend print save as pdf

Related Stories

Best use of drug-eluting stents

Sep 02, 2008

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use ...

Results of the DESERT registry reported at TCT 2011

Nov 09, 2011

The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

Drug-Eluting stents reduce risk of thrombosis

Mar 23, 2012

(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting ...

Results of the EVOLVE trial reported at TCT 2011

Nov 11, 2011

A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today ...

Recommended for you

Fish oil supplements don't prevent recurrence of A-fib

2 hours ago

(HealthDay)—High doses of fish oil supplements won't prevent recurrence of atrial fibrillation (AF), Canadian researchers report. The study, funded by the Canadian Institutes for Health Research and the ...

User comments